Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Upholding its principles of “no further reverse stock splits” and prudent equity issuances, the Company is committed to ...

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 6,487,879 shares of common stock at $33.00 per share, along with pre-funded warrants for 1,112,121 shares at $32.999 each, aiming to raise approximately $251 million before expenses [1][2]. Group 1: Offering Details - The offering includes a total of 6,487,879 shares of common stock priced at $33.00 each and pre-funded warrants for 1,112,121 shares priced at $32.999 each, with an exercise price of $0.001 per share [1]. - The expected gross proceeds from the offering are approximately $251 million, excluding underwriting discounts and commissions [1]. - The offering is set to close on September 11, 2025, subject to customary closing conditions, and underwriters have a 30-day option to purchase an additional 1,140,000 shares [1]. Group 2: Use of Proceeds - Dianthus intends to utilize the net proceeds from the offering to advance its preclinical and clinical development activities, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].

SOMPO uses Radar to accelerate data-driven management across pricing, underwriting and portfolio optimization, and with Sompo Direct Insurance Inc. implementing Radar as its rate calculation engine.TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, and Sompo Holdings, Inc., one of Japan’s leading insurance groups, today announced a global partnership to deploy WTW’s Radar technology across SOMPO Group. This marks the first global agreement ...

VANCOUVER, British Columbia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Prime Mining Corp. (“Prime” or the “Company”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) announced today that it has filed its notice of meeting and management information circular (the “Circular”) with securities regulators in connection with the special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares of the Company (the “Prime Shares”), the holders (the “Option Holders”) of options to purchase Prime Shares (the ...

Core Viewpoint - Rapport Therapeutics, Inc. has announced a public offering of 9,615,385 shares at a price of $26.00 per share, aiming to raise approximately $250 million in gross proceeds before expenses [1][3]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, which allows for a differentiated approach in drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,442,307 shares at the public offering price [1]. - The offering is expected to close around September 11, 2025, pending customary closing conditions [1]. - Goldman Sachs, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers for the offering [2].

New York, NY, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Trailblazer Acquisition Corp. (the “Company”) announced today the pricing of its upsized initial public offering of 24,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading on September 10, 2025, under the ticker symbol “BLZRU.” Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, each whole warrant entitling the holder thereof t ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study1) is the first registration-enabling study to evaluate whether the ...

St. Petersburg, Fla., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Raymond James Financial, Inc. (NYSE: RJF) (“Raymond James” or the “Company”) today announced the pricing of a registered underwritten public offering of (i) $650,000,000 aggregate principal amount of 4.900% senior notes due 2035 (the “2035 Notes”) and (ii) $850,000,000 aggregate principal amount of 5.650% senior notes due 2055 (the “2055 Notes” and, together with the 2035 Notes, the “Notes”). The 2035 Notes will bear interest at a rate of 4.900% per a ...

Core Viewpoint - Capital Southwest Corporation has announced a public offering of $350 million in 5.950% notes due 2030, with a yield-to-maturity of 6.104% [1][2]. Group 1: Offering Details - The notes will mature on September 18, 2030, and can be redeemed at par plus a "make-whole" premium before August 18, 2030 [1]. - The offering price is set at 99.345% of the aggregate principal amount of the notes [1]. - The offering is expected to close on September 18, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to redeem the outstanding 7.75% Notes due 2028 and 3.375% Notes due 2026 [2]. - A portion of the proceeds will also be used to repay outstanding indebtedness under the Corporate Credit Facility and/or the SPV Credit Facility [2]. - The company plans to re-borrow under these facilities to make investments aligned with its investment objectives and for general corporate purposes [2]. Group 3: Underwriters - Deutsche Bank Securities Inc., ING Financial Markets LLC, Morgan Stanley & Co. LLC, SMBC Nikko Securities America, Inc., and Wells Fargo Securities, LLC are acting as active bookrunners for the offering [3]. - Citizens JMP Securities, LLC and Raymond James & Associates, Inc. are serving as passive bookrunners [3]. - B. Riley Securities, Inc., Oppenheimer & Co. Inc., and UBS Investment Bank are co-managers for the offering [3]. Group 4: Company Overview - Capital Southwest Corporation is a Dallas-based business development company with approximately $1.8 billion in investments at fair value as of June 30, 2025 [7]. - The company focuses on middle market lending, supporting acquisitions and growth of businesses with investments ranging from $5 million to $50 million [7]. - As a public company with a permanent capital base, Capital Southwest has the flexibility to provide creative financing solutions [7].

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- PrimeEnergy Resources Corporation (NASDAQ: PNRG) announced that it has been recognized in two prestigious rankings of corporate performance. The Houston Chronicle ranked PrimeEnergy **9th overall** in its Chronicle 100 list of Houston’s top-performing public companies, which evaluates revenue growth, earnings per share growth, and total shareholder return. At the national level, Forbes recognized PrimeEnergy as the **#6 company in the Oil & Gas Operations category ...